Child-Friendly version of EQ-5D will be discussed to realize the final version of the questionnaire.

DEVELOPMENT OF AN ICIQ NOCTURNAL ENURESIS QOL QUESTIONNAIRE

Holm-Larsen T1, Hansen M2, Riis A2, Gennaro M3, Hagstrom S2, Nergaard JP5
1University of Pharmaceutical Sciences, Copenhagen, Denmark, 2Ferring Pharmaceuticals A/S, Copenhagen, Denmark, 3Bambino Gesù Children’s Hospital, Rome, Italy, 4Hospital of Skejby, Aarhus, Denmark, 5Ferring Pharmaceuticals, Copenhagen, Denmark

OBJECTIVES: There is a lack of a validated QoL questionnaire assessing the psychological burden and treatment benefits of bed-wetting as evaluated by the child. This abstract reports the results of the initial validation tests for such a questionnaire. It is being developed in accordance with the validation standards of the ICIQ. METHODS: A literature review was conducted and led to quantitative interviews with 28 children suffering from Nocturnal Enuresis and 28 pairs of parents. Consequently a questionnaire including 20 questions was developed and tested in a multinational Randomised Clinical Trial completed by 196 children and 196 parents in antidiuretic treatment before and during the trial. RESULTS: Based on review and interviews, a list of issues was identified: Social isolation, emotional distress, low self-esteem, problems in parent-child relation, delayed independence and fear of being teased at school and home. Two or more questions were developed for each of the six issues to add room for elimination of poorly performing questions. The RCT data indicated promising cluster effect, i.e. the well treated children showed a high QoL, and the questions seemed test-retest consistent. Some questions yield a high level of missing answers. CONCLUSION: The tests led to reformulation of the questions yielding missing answers and the questionnaire is now ready for the coming validation, including sensitivity analysis and item reduction. We are convinced that future research in Nocturnal Enuresis will profit from the final questionnaire.

TREATMENT DURATION FOR ATROPHIC VAGINITIS: CLINICAL TRIALS VERSUS “THE REAL WORLD”

Balu S1, Lee WC2, Joshi AV1, Cobden D1, Pashos CL1
1Abt Associates Inc, Lexington, MA, USA, 2Abt Associates Inc, Bethesda, MD, USA, 3Novo Nordisk Inc, Princeton, NJ, USA

OBJECTIVE: Duration of vaginal estrogen therapy (VET) may vary. This study sought to compare and contrast treatment duration of women prescribed vaginal tablets (VT) or vaginal creams (VC) in clinical trials with that in clinical practice. METHODS: Adults initiating VET between January and June, 2004 in 57 managed care plans (PharMetrics database) in the United States were identified and followed for up to 10 months to examine their treatment duration. A Kaplan-Meier analysis was performed to obtain average and median time to discontinuation for individuals treated with VT or VC. A weighted average of treatment duration was calculated for a total of seven clinical trials identified in the literature. These results were stratified by study inclusion criteria. Differences in average treatment duration were statistically tested using t-tests. RESULTS: Of 5599 patients undergoing VET (mean age = 54 ± 9.1 years), 4355 (77.8%) received VC and 1244 (22.2%) received VT. Patients prescribed VT had a significantly longer average (median) treatment compared to patients prescribed VC [(198.5 ± 82.4 days (221 days) vs. 177.1 ± 86.7 days (190 days); p < 0.01)]. This duration in clinical practice was significantly longer than that in seven clinical trials [165 days (240 days for three trials of both VC and VT; 90 days for two VT-only studies; and 69 days for two VC-only studies)]. CONCLUSIONS: Duration of VET was longer in a real-world clinical practice setting than in clinical trials. Moreover, subjects treated with VT exhibited significantly longer treatment duration than subjects treated with VC. Possible factors explaining longer duration with VT include ease of use, reduced messiness, accurate dosing resulting in improved effectiveness and fewer adverse events, and consequently improved quality of life. Future studies should prospectively examine factors associated with these differences.

ASSESSING PSYCHOLOGICAL BURDEN AND TREATMENT BENEFITS IN PEDIATRIC PATIENTS WITH BEDWETTING

Weinstein D1, Sendersky V1, Holm-Larsen T2, Nergaard JP1
1Ferring Pharmaceuticals, Copenhagen, Denmark, 2University of Pharmaceutical Sciences, Copenhagen, Denmark

OBJECTIVES: Nocturnal enuresis (NE) can pose significant psychological burden on children’s self-esteem and quality of life (QoL). Therefore, patient-reported outcome (PRO) measurement is essential to fully understand the burden posed by NE and the benefits of treating this condition. To our knowledge, it has not been investigated which instruments should be used to assess the psychological burden of NE. The aim of this study was to identify and evaluate PRO instruments used in children with NE. METHODS: A literature search of Medline and other databases was conducted to identify publications from 1995–2006 which contained PRO instruments used in children with NE. RESULTS: 40 studies and 32 PRO instruments were identified. Instruments were evaluated based on psychometric properties and responsiveness to change. Some studies used several PRO instruments. The Child Behavior Checklist was the most commonly used instrument (8/40 studies, 20%). Measures of self-esteem were used in 11/40 studies (28%). No generic QoL measures were used in these trials. No disease-specific PRO instruments were found to be fully validated in the NE population. Currently, a new disease-specific QoL questionnaire is in development for NE. CONCLUSIONS: The results of this study highlight the lack of patient-reported disease-specific PRO measures to assess the burden and treatment benefits of NE. A new disease-specific instrument may be able to fill this gap.

DIMENSIONS OF HRQOL AND SATISFACTION WITH LIFE IMPROVE IN ED PATIENTS SWITCHING FROM OTHER ORAL ED MEDICATION TO TADALAFIL

Taipale K1, Fugl-Meyer A1, Leinonen M1, Leinonen ES1, Sintonen H1
1OY Eli Lilly Finland Ab, Vantaa, Finland, 2University of Uppsala, Uppsala, Sweden, 3OY ‘4Pharma Ltd. Kista, Sweden, 4University of Helsinki, Helsinki, Finland

OBJECTIVES: To compare Finnish patients with erectile dysfunction (ED) and men from the Finnish general population in measures of self-reported Health-Related QOL (HRQoL) and satisfaction with life, and to investigate whether switching patients from current oral ED medication to tadafalil impacts these measures. METHODS: A total of 202 Finnish men over 18 years successfully treated with oral ED prescription medication (tadafalil excluded) voluntarily entered this multicenter, open-label, one-arm, 3-month study. Upon enrollment, patients discontinued their previous therapy and were started on tadafalil 10 or 20 mg (dose determined by investigator) on demand. Outcome was measured using the 15D and Life Satisfaction-11 (LiSat-11) checklists. 15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of HRQoL.
used as both a profile and single score measure. LiSat-11 is a generic validated checklist for self-perceived satisfaction with life. A Finnish, age-matched male population cohort was used for comparison. RESULTS: A total of 194 patients provided data for analysis at baseline and outcome at 3 months. The changes observed (baseline to endpoint) were as follows: average usage of ED tablets per four weeks increased from 4.7 to 9.7, intercourse attempts from 6.4 to 10.6, and the success rate of intercourse from 79% to 92%. At baseline, the 1SD score was higher for the study patients than for the comparator population (0.924 vs. 0.902). Nevertheless, significant improvement (baseline to endpoint) was reported on the 15D dimensions of mobility, depression, distress (all p < 0.01), and sexual activity (p < 0.001); and in general (p < 0.05), leisure (p < 0.01), sexual life, family life, and partnership relation (all p < 0.001) domains of LiSat-11. CONCLUSIONS: When patients switched from other oral ED medication to tadalafil, improvement was seen in 3 of 15 dimensions of 15D and in 5 out of 11 domains of LiSat-11, including the closeness items: sexual life, partnership relation, and family life.

**ESTIMATING UTILITY IN ROTAVIRUS GASTROENTERITIS IN CHILDREN UNDER FIVE IN THE UK**

Martín A1, Cotrell S2

1GlaxoSmithKline UK Limited, Uxbridge, UK, 2IMS Health, London, England

**OBJECTIVE:** To estimate the health state utility of differing severities of gastro-enteritis associated with rotavirus infection in children under five.

**METHODS:** Health state descriptions were developed based on the major symptoms of gastro-enteritis infection. Health states for children who could be treated at home and those requiring hospitalisation were presented to GPs (N = 25), and for hospitalised cases, health states for children with two levels of dehydration were presented to paediatricians (N = 25).

Both GPs and paediatricians were asked to score these health states using the EQ-5D questionnaire for children in two age bands (< 18 months, 1.5–5 years). Scores were modified to take into account the limited capacity for mobility and self-care among children in this age range. Utility estimates were calculated from these scores using standard methodology.

**RESULTS:** From GP scores subjects requiring or not hospitalisation have a mean utility value (95% CI) of 0.425 (95 CI: 0.330; 0.520) and 0.781 (95 CI: 0.678; 0.884) in children <18 months, and 0.200 (95 CI: 0.049; 0.352) and 0.688 (95 CI: 0.553; 0.824) in children 1.5 yrs–5 yrs respectively. From paediatrician scores, mean utility values for hospitalised cases with 3–8% dehydration were presented to paediatricians (N = 25).

Both GPs and paediatricians were asked to score these health states using the EQ-5D questionnaire for children in two age bands (< 18 months, 1.5–5 years). Scores were modified to take into account the limited capacity for mobility and self-care among children in this age range. Utility estimates were calculated from these scores using standard methodology.

**RESULTS:** From GP scores subjects requiring or not hospitalisation have a mean utility value (95% CI) of 0.425 (95 CI: 0.330; 0.520) and 0.781 (95 CI: 0.678; 0.884) in children <18 months, and 0.200 (95 CI: 0.049; 0.352) and 0.688 (95 CI: 0.553; 0.824) in children 1.5 yrs–5 yrs respectively. From paediatrician scores, mean utility values for hospitalised cases with 3–8% and ≥9% dehydration were 0.595 (95 CI: 0.528; 0.662) and 0.256 (95 CI: 0.157; 0.354) in children <18 months, and 0.634 (95 CI: 0.549; 0.718) and 0.077 (95 CI: 0.057; 0.210) in children 1.5 yrs–5 yrs respectively. In each case, confidence intervals between severe and less severe health states did not overlap.

**CONCLUSION:** Gastroenteritis associated with rotavirus has a significant impact on the health related quality of life in children under five. This study provides useful estimates of health state utilities for economic evaluation of interventions to prevent rotavirus infection.

**INFLUENCE OF CONCOMITANT DISEASES ON THE CLINICAL RESPONSE TO TREATMENT FOR ERECTILE DYSFUNCTION**

Gutiérrez del Pozo R1, Carderosa O2, Pérez M3, Artes M4

1Adelphi TARGET, Barcelona, Spain, 2IMS Health, London, England

**OBJECTIVE:** To determine the clinical response to treatment (patient satisfaction, onset of action and reproducibility of the effect) in patients with ED, with or without other concomitant diseases.

**METHODS:** A retrospective, epidemiological study was conducted in which we collected demographic data, medical and sexual history, concomitant medication, diagnostic and therapeutic procedures applied to ED and the clinical response to the prescribed treatment in male patients over 18 years of age who had visited their doctor in the 3 months prior to the start of the study.

**RESULTS:** Data was collected from 5281 patients. The most prevalent associated disorders were cardiovascular (28.6%), endocrine (23.7%) and genitourinary (15.4%). A total of 77.1% of the patients with concomitant disorders indicated they were satisfied with the erection obtained (sufficient for intercourse) (90.9% of the patients without other associated disorders; p < 0.0001). A total of 77.1% of the patients with concomitant disorders indicated they were satisfied with the erection obtained (sufficient for intercourse) (91.1% without other associated disorders; p < 0.0001). 75.8% of the patients with concomitant diseases were confident to obtain and maintain a sufficient erection at each new attempt (90.0% without other associated disorders; p < 0.0001). Clinical response was better in patients with cardiovascular or endocrine conditions vs. genitourinary disorders (p < 0.03; p < 0.04). The mean prescribed dose was 15.9 mg (SD 5.2) of vardenafl, 18.6 mg (SD 6.9) of tadalafil and 60.6 mg (SD 23.7) of vardenafl.